Basit öğe kaydını göster

dc.contributor.authorPEHLİVAN, Sacide
dc.contributor.authorSerin, Istemi
dc.contributor.authorOyaci, Yasemin
dc.contributor.authorPehlivan, Mustafa
dc.date.accessioned2022-07-04T13:16:21Z
dc.date.available2022-07-04T13:16:21Z
dc.identifier.citationSerin I., Oyaci Y., Pehlivan M., PEHLİVAN S., "Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms", Cytokine, cilt.153, 2022
dc.identifier.issn1043-4666
dc.identifier.otherav_4176c6c7-db4a-4af4-a424-9986cec78adb
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/182479
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85125770616&origin=inward
dc.identifier.urihttps://doi.org/10.1016/j.cyto.2022.155851
dc.description.abstract© 2022 Elsevier LtdIntroduction: The IL-1 receptor antagonist (IL-1Ra or IL-1RN) is a member of the IL-1 superfamily that functions as a competitive antagonist of the cell surface IL-1 receptor, thereby regulating various immune and inflammatory responses related to IL-1. IL-1 induces tumor growth and metastasis, while IL-1RN inhibits the secretion of IL-1α and IL-6 in cancer cells. Interleukin-4 (IL-4) is a potent anti-inflammatory cytokine, can be secreted by many types of immune cells. In this study, it was aimed to reveal the effects of IL-1RN and IL-4 VNTR polymorphisms on disease development and survival in patients with multiple myeloma (MM). Material and methods: In this study, 244 patients diagnosed with MM in hematology clinic between January 2010 and January 2021, and 179 healthy individuals were included. The genotypes of the IL-1RN VNTR polymorphism were statistically compared before treatment between patients having undergone stem cell transplantation and healthy controls, as were the genotypes of IL-4 VNTR polymorphism. Additionally, the statistically significant effects of these genotypes on survival were examined. Results: In the statistical analysis of the distribution of IL-1RN VNTR gene variants, 1/3 and 1/4 genotypes were found to be significantly higher in patients with MM compared to the healthy controls (p = 0.035). There was no significant difference between the MM patient group and the healthy controls in terms of IL-4 VNTR genotype distribution. PFS of patients with IL-1RN VNTR non-2-allele carrier genotypes was significantly shorter, but no significant effect was found on OS (p = 0.03, p = 0.786, respectively). Patients with IL-1RN VNTR non-2-allele carrier genotypes had 1.718-fold increased risk of shorter PFS. Conclusions: In conclusion, with this study, the effects of IL-1RN VNTR and IL-4 VNTR polymorphisms on MM were evaluated for the first time in the literature. This study will shed light on ones on cytokine-MM relationship and epigenetic mechanisms.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectImmunology and Allergy
dc.subjectHealth Sciences
dc.subjectImmunology
dc.subjectLife Sciences
dc.subjectBiochemistry
dc.subjectMolecular Biology
dc.subjectHematology
dc.subjectYaşam Bilimleri
dc.subjectSitogenetik
dc.subjectTemel Bilimler
dc.subjectHematoloji
dc.subjectALERJİ
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectİmmünoloji
dc.subjectKlinik Tıp
dc.subjectMoleküler Biyoloji ve Genetik
dc.titleRole of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms
dc.typeMakale
dc.relation.journalCytokine
dc.contributor.departmentUniversity of Health Sciences , ,
dc.identifier.volume153
dc.contributor.firstauthorID3405972


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster